Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (200)	11/3/1997 10:40:00 PM
From: Andrew H	Respond to of 353

MZ--SQNA definately got the better of it today. I think ARRS is a steal under 11. I told them on the VD thread I thought that should be their next buy. ARRS will soon start looking very cheap as the bios rally.

To: Miljenko Zuanic who wrote (200)	11/4/1997 12:12:00 AM
From: James Silverman	Respond to of 353

Miljenko, John etc, I bought some SQNA mid-day as a cheaper way to buy into the merged entity. I like the deal. Integration of the various platforms is the way the biotech industry is moving and ARRS has made it pretty clear this was their plan quite a ways back. Combining functional genomics, SBDD, chemistry, biology, screening and genomics etc should make a powerful unit. The closest companies to this are MLNM (powerhouse) and the former ONCS (can't recall their new name). I'd suspect this won't be the last ARRS merger as they still don't have all the pieces of the puzzle in place as listed above.